Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies

Pediatric Transplantation

Volumn 18, Issue 8, 2014, Pages 839-850

  Crins, Nicola D ^a,b   Röver, Christian ^a   Goralczyk, Armin D ^c   Friede, Tim ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Department of Internal Medicine   (Germany)

^c Department of Internal Medicine   (Germany)

Author keywords

Basiliximab; Controlled study; Daclizumab; Immunosuppression; Interleukin 2 receptor antagonist; Liver transplantation; Meta analysis; Pediatric

Indexed keywords

BASILIXIMAB; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; SYSTEMATIC REVIEW;

EID: 84964224945     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12362     Document Type: Article

References (39)

1. GIBELLI NEM, PINHO-APEZZATO ML, MIYATANI H.T., et al. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: Comparative study. Transplant Proc 2004: 36: 956-957.
2. SCHULLER S, WIEDERKEHR JC, COELHO-LEMOS IM, AVILLA S.G., SCHULTZ C. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Transplant Proc 2005: 37: 1151-1152.
3. HEFFRON TG, PILLEN T, SMALLWOOD G.A., WELCH D., OAKLEY B, ROMERO R. Pediatric liver transplantation with daclizumab induction therapy. Transplantation 2003: 75: 2040-2043.
4. OOSTERLEE A, RAHMEL A (eds). Eurotransplant International Foundation Annual Report 2011. Leiden: Eurotransplant Foundation. Available at: http://www.eurotransplant.org/cms/mediaobject.php?file=ar-2011.pdf (Accessed September 4, 2014).
5. 2009 OPTN/SRTR Annual Report 1999-2008. Rockville, MD, USA: HHS/HRSA/HSB/DOT. Available at: http://www.ustransplant.org/annual-reports/current (Accessed September 4, 2014).
6. PARTY IW. Terminology for hepatic allograft rejection. International working party. Hepatology 1995: 22: 648-654.
7. VINCENTI F, KIRKMAN R, LIGHT S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161-165.
8. SEBAGH M, BLAKOLMER K, FALISSARD B., et al. Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: Reliability of the 1999 Banff schema. Hepatology 2002: 35: 1.
9. SPADA M, PETZ W, BERTANI A., et al. Randomized trial of basil-iximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006: 6: 1913-1921.
10. GRAS JM, GERKENS S, BEGUIN C., et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: Clinical and pharmacoeconomic study in 50 children. Liver Transpl 2008: 14: 469-477.
11. PASCUAL J, MARCEN R, ORTUNO J. Anti-interleukin-2 receptor antibodies: Basiliximab and daclizumab. Nephrol Dial Transplant 2001: 16: 1756-1760.
12. QUEEN C, SCHNEIDER WP, SELICK H.E., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989: 86: 10029-10033.
13. NASHAN B, MOORE R, AMLOT P., SCHMIDT AG, ABEYWICKRAMA K, SOULILLOU JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997: 350: 1193-1198.
14. DI FILIPPO S. Anti-IL-2 receptor antibody vs. polyclonal antilymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 2005: 9: 373-380.
15. HIGGINS J, GREEN S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 updated September 2009. The Cochrane Collaboration, 2009. Available at: http://www.cochranehandbook.org.
16. MOHER D, LIBERATI A, TETZLAFF J., ALTMAN DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009: 6: e1000097.
17. GORALCZYK AD, HAUKE N, BARI N., TSUI TY, LORF T, OBED A. Interleukin 2 receptor antagonists for liver transplant recipients: A systematic review and metaanalysis of controlled studies. Hepatology 2011: 54: 541-554.
18. TIPPNER C, NASHAN B, HOSHINO K., et al. Clinical and subclinical acute rejection early after liver transplantation: Contributing factors and relevance for the long-term course. Transplantation 2001: 72: 1122-1128.
19. DEEKS JJ, ALTMAN DG, BRADBURN MJ Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EGGER M, DAVEY SG, ALTMAN DG, eds. Systematic Reviews in Healthcare, 2nd edn. London: BMJ Books, 2001: pp. 285-311.
20. VIECHTBAUER W. Conducting meta-analyses in R with the meta for package. J Stat Softw 2010: 36: 1-48.
21. VIECHTBAUER W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med 2007: 26: 37-52.
22. HIGGINS JPT, THOMPSON SG, DEEKS J.J., ALTMAN DG. Measuring inconsistency in meta-analyses. BMJ 2003: 327: 557-560.
23. EGGER M, DAVEY SG, SCHNEIDER M, MINDER C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997: 315: 629-634.
24. R DEVELOPMENT CORE TEAM. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2010. ISBN 3-900051-07-0. Available at: http://www.r-project.org (Accessed September 4, 2014).
25. SCHWARZER G. meta: Meta-Analysis with R. R package version 1.6-1. 2010. Available at: http://cran.r-project.org/package=meta (Accessed September 4, 2014).
26. BATES D, MAECHLER M. Lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-35. 2010. Available at: http://cran.r-project.org/package=lme4
27. GANSCHOW R, GRABHORN E, SCHULZ A., von HUGO A, ROGIERS X, BURDELSKI M. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr Transplant 2005: 9: 741-745.
28. DEMETRIS AJ, BATTS KP, DHILLON A.P., et al. Banff schema for grading liver allocraft rejection: An international consensus document. Hepatology 1997: 25: 353-358.
29. SWIATECKA-URBAN A., GARCIA C, FEUERSTEIN D., et al. Basiliximab induction improves the outcome of renal transplants in children and adolescents. Pediatr Nephrol 2001: 16: 693-696.
30. VESTER U, KRANZ B, TESTA G., et al. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr Transplant 2001: 5: 297-301.
31. VESTER U, KRANZ B, TESTA G., MALAGO M, BROELSCH CE, HOYER PF Basiliximab as induction therapy in pediatric renal transplantation: Single center experience from Essex, Germany. Pediatr Transplant 2000: 4: 85.
32. SWEET SC, DE LA MORENA MT, SHAPIRO SD, MENDELOFF EN, HUDDLESTON CB. Interleukin-2 receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplantation. J Heart Lung Transplant 2001: 20: 221.
33. REDDY SC, LAUGHLIN K, WEBBER SA Immunosuppression in pediatric heart transplantation: 2003 and beyond. Curr Treat Options Cardiovasc Med 2001: 5: 417-428.
34. PIETRA BA, BOUCEK MM Immunosuppression for pediatric cardiac transplantation in the modern era. Prog Pediatr Cardiol 2000: 11: 115-129.
35. GRUNDY N, SIMMONDS J, DAWKINS H., REES P, AURORA P, BURCH M. Preimplantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation. J Heart Lung Transplant 2009: 28: 1279-1284.
36. FORD KA, CALE CM, REES P.G., ELLIOTT MJ, BURCH M. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 2005: 24: 1284-1288.
37. EUROPEAN MEDICINES AGENCY (EMEA). European Public Assessment Report (APAR) Simulect - EPAR summary for the public. 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000207/WC500053541.pdf (Accessed September 4, 2014).
38. EUROPEAN MEDICINES AGENCY (EMEA). European Public Assessment Report (APAR) Zenapax - EPAR summary for the public. 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000198/WC500057570.pdf (Accessed September 4, 2014).
39. WEBSTER AC, PLAYFORD EG, HIGGINS G, CHAPMAN JR, CRAIG JC. Interleukin 2 receptor antagonists for renal transplant recipients: A metaanalysis of randomized trials. Transplantation 2004: 77: 166-176.